Evidence map›Paper›PMID 40944318›Full record

ArticleJournal of Alzheimer's disease : JAD2026

The predictive role of olfactory identification on episodic memory and mild cognitive impairment: Results from the CIMA-Q cohort.

Benoît Jobin, Natalie A Phillips, Johannes Frasnelli, Benjamin Boller, CIMA-Q group

Abstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Benoît JobinDepartment of Psychology, Université du Québec à Trois-Rivières, Trois-Rivières, Quebec, Canada.ORCID 0000-0002-1357-5116
Natalie A PhillipsDepartment of Psychology, Concordia University, Montréal, Quebec, Canada.
Johannes FrasnelliResearch Centre of the Institut universitaire de gériatrie de Montréal, Montréal, Quebec, Canada.
Benjamin BollerDepartment of Psychology, Université du Québec à Trois-Rivières, Trois-Rivières, Quebec, Canada.ORCID 0000-0002-6184-1933
CIMA-Q group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundOlfactory identification decline is a known early marker of Alzheimer's disease and is already present at the mild cognitive impairment (MCI) stage. While being linked with episodic memory, its predictive value for cognitive performance and distinguishing between clinical stages remains unclear.ObjectiveThis study examined (1) the predictive value of olfactory identification for episodic memory performance and (2) its utility for discriminating individuals with MCI from those with subjective cognitive decline (SCD).MethodsParticipants included 45 individuals with MCI (mean age = 80.08, SD = 5.86) and 48 with SCD (mean age = 75.82, SD = 5.64) from the Consortium for the Early Identification of Alzheimer's Disease-Quebec cohort. We evaluated olfactory identification with the University of Pennsylvania Smell Identification Test (UPSIT), and episodic memory with the Rey Auditory Verbal Learning Test (RAVLT). LASSO regression models were used to predict RAVLT total and delayed recall scores, using 80% of data for training and 20% for testing.ResultsUPSIT significantly predicted both RAVLT total (β = 0.45,

Indexed as

Cognitive DysfunctionMemory, EpisodicOlfactory PerceptionSmellAgedAged, 80 and overCohort StudiesFemaleHumansMaleNeuropsychological TestsPredictive Value of TestsAlzheimer's diseaseepisodic memorymild cognitive impairmentolfactory identificationsubjective cognitive decline

Identifiers

PMID40944318
PMCPMC12953685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.